{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:18:51Z","timestamp":1762867131205,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mundipharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00432-017-2439-x","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T15:31:33Z","timestamp":1495467093000},"page":"2049-2058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Successful treatment of patients with newly diagnosed\/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)"],"prefix":"10.1007","volume":"143","author":[{"given":"Hannah","family":"Tessenow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madlen","family":"Holzvogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Holzvogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Heyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schliwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maik","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Zehrfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Pfrepper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Krahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Leiblein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Bill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thoralf","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9666-6274","authenticated-orcid":false,"given":"Wolfram","family":"P\u00f6nisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"key":"2439_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2336","author":"I Avivi","year":"2016","unstructured":"Avivi I, Cohen YC, Joffe E, Benyamini N, Held-Kuznetsov V, Trestman S, Terpos E, Dimopoulos MA, Kastritis E (2016) Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. Hematol Oncol. doi: 10.1002\/hon.2336 (Epub ahead of print)","journal-title":"Hematol Oncol"},{"key":"2439_CR2","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood.V122.21.3193.3193","volume":"122","author":"JG Berdeja","year":"2013","unstructured":"Berdeja JG, Savona MR, Chu L, Essell J, Murphy P, Bauer T, Raefsky E, Boccia RV, Flinn IW (2013) Bendamustine, bortezomib and dexamethasone (BBD) as first-line treatment of patients (pts) with multiple myeloma who are not candidates for high dose chemotherapy: toxicity comparison of two dose schedules. Blood 122:3193 (abstract)","journal-title":"Blood"},{"key":"2439_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bjh.12129","volume":"160","author":"JR Berenson","year":"2013","unstructured":"Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D (2013) Phase I\/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 160:321\u2013330","journal-title":"Br J Haematol"},{"key":"2439_CR4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ajh.24107","volume":"90","author":"M Binder","year":"2015","unstructured":"Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Lust JA, Kapoor P, Lin Y, Go RS, Hwa YL, Kyle RA, Kumar SK (2015) Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. Am J Hematol 90:888\u2013891","journal-title":"Am J Hematol"},{"issue":"22","key":"2439_CR5","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1182\/blood-2013-12-542662","volume":"123","author":"A Brioli","year":"2014","unstructured":"Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, Jackson GH, Gregory WM, Owen RG, Child JA, Davies FE, Cavo M, Drayson MT, Morgan GJ (2014) Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood 123(22):3414\u20133419","journal-title":"Blood"},{"key":"2439_CR6","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","volume":"22","author":"MA Dimopoulos","year":"2008","unstructured":"Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485\u20131493","journal-title":"Leukemia"},{"key":"2439_CR7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3816\/CLM.2009.n.059","volume":"9","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M (2009a) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib based regimes: identification of predictive factors. Clin Lymphoma Myeloma 9:302\u2013306","journal-title":"Clin Lymphoma Myeloma"},{"key":"2439_CR8","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","volume":"27","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF (2009b) VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 27:6086\u20136093","journal-title":"J Clin Oncol"},{"key":"2439_CR9","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Gavo M, Rajkumar SV, Durie BGM, Miguel JS (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976\u20134984","journal-title":"J Clin Oncol"},{"key":"2439_CR10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2012.182","volume":"27","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, Matsouka C, Spyropoulou-Vlachou M, Terpos E, Kastritis E (2013) The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 27:423\u2013429","journal-title":"Leukemia"},{"key":"2439_CR11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdt483","volume":"25","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A, Konstantopoulos K, Terpos E, Kastritis E (2014) Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25:195\u2013200","journal-title":"Ann Oncol"},{"key":"2439_CR12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842\u2013854","journal-title":"Cancer"},{"key":"2439_CR13","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belc A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, on behalf of the International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"issue":"1","key":"2439_CR14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/ndt\/gfv283","volume":"31","author":"L Ecoti\u00e8re","year":"2016","unstructured":"Ecoti\u00e8re L, Thierry A, Debiais-Delpech C, Chevret S, Javaugue V, Desport E, Belmouaz S, Quellard N, Kaaki S, Goujon J, Fermand J-P, Touchard G, Bridoux F (2016) Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transpl 31(1):64\u201372","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"2439_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","volume":"48","author":"V Eleutherakis-Papaiakovou","year":"2007","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, Michali E, Economopuos T, Zervas K, Dimopoulos MA, on behalf of the Greek Myeloma Study Group (2007) Renal failure in multiple myeloma: incidence, correlations and prognostic significance. Leuk Lymphoma 48(2):337\u2013341","journal-title":"Leuk Lymphoma"},{"issue":"Suppl. 13","key":"2439_CR16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/sonc.2002.34872","volume":"29","author":"V Gandhi","year":"2002","unstructured":"Gandhi V (2002) Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 29(Suppl. 13):4\u201311","journal-title":"Semin Oncol"},{"key":"2439_CR17","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1038\/bcj.2015.20","volume":"5","author":"WI Gonsalves","year":"2015","unstructured":"Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust S, Kyle RA, Gertz MA, Kumar SK (2015) Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 5:e296. doi: 10.1038\/bcj.2015.20","journal-title":"Blood Cancer J"},{"key":"2439_CR18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/ndt\/gfp488","volume":"25","author":"RJ Haynes","year":"2010","unstructured":"Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG (2010) Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transpl 25:419\u2013426","journal-title":"Nephrol Dial Transpl"},{"key":"2439_CR19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3324\/haematol.10759","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA (2007) Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92:546\u2013549","journal-title":"Haematologica"},{"key":"2439_CR20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","volume":"53","author":"LM Knudsen","year":"1994","unstructured":"Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J (1994) Renal function in newly diagnosed multiple myeloma\u2014a demographic study of 1353 patients. Eur J Haematol 53:207\u2013212","journal-title":"Eur J Haematol"},{"key":"2439_CR21","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Rusell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520","journal-title":"Blood"},{"key":"2439_CR22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp P (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21\u201333","journal-title":"Mayo Clin Proc"},{"key":"2439_CR23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461\u2013470","journal-title":"Ann Intern Med"},{"key":"2439_CR24","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","volume":"28","author":"H Ludwig","year":"2010","unstructured":"Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N (2010) Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 28:4635\u20134641","journal-title":"J Clin Oncol"},{"key":"2439_CR25","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","volume":"123","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weissmann A, Adam Z (2014) Bendamustine-bortezomib-dexamethasone (BBD) is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123:985\u2013991","journal-title":"Blood"},{"issue":"8","key":"2439_CR26","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3324\/haematol.2015.124818","volume":"100","author":"M-V Mateos","year":"2015","unstructured":"Mateos M-V, Oriol A, Rosinol L, de Arriba F, Puig N, Martin J, Martinez-Lopez J, Echeveste MA, Sarra J, Ocio EM, Ramirez G, Martinez R, Palomera L, Payer A, Iglesias R, de la Rubia J, Alegre A, Chinea AI, Blade J, Lahuerta JJ, San Miguel JF (2015) Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish\/Pethesma trial. Haematologica 100(8):1096\u20131102. doi: 10.3324\/haematol.2015.124818","journal-title":"Haematologica"},{"issue":"3","key":"2439_CR27","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1038\/bcj.2013.58","volume":"22","author":"M Offidani","year":"2013","unstructured":"Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P, Olivieri A, Leoni P (2013) Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: a phase II study. Blood Cancer J 22(3):e162. doi: 10.1038\/bcj.2013.58","journal-title":"Blood Cancer J"},{"key":"2439_CR28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","volume":"132","author":"W P\u00f6nisch","year":"2006","unstructured":"P\u00f6nisch W, Mitrou PS, Merkle K-H, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone\u2014a randomized phase III study of the East German Study Group of Haematology and Oncology (OSHO). J Cancer Res Clin Oncol 132:205\u2013212","journal-title":"J Cancer Res Clin Oncol"},{"key":"2439_CR29","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00432-012-1212-4","volume":"138","author":"W P\u00f6nisch","year":"2012","unstructured":"P\u00f6nisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, Zehrfeld T, Schwarz M, Winkelmann C, Petros S, Bachmann A, Lindner T, Niederwieser D (2012) Successful treatment of patients with newly diagnosed\/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 138:1405\u20131412","journal-title":"J Cancer Res Clin Oncol"},{"key":"2439_CR30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00432-012-1339-3","volume":"139","author":"W P\u00f6nisch","year":"2013","unstructured":"P\u00f6nisch W, Bourgeois M, Moll B, Heyn S, J\u00e4kel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, A\u00dfmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Sch\u00f6nfelder U, Zehrfeld T, Hensel G, L\u00f6schcke K, Krahl R, Al-Ali H, Niederwieser D (2013) Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 139:499\u2013508","journal-title":"J Cancer Res Clin Oncol"},{"key":"2439_CR31","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00432-015-1984-4","volume":"141","author":"W P\u00f6nisch","year":"2015","unstructured":"P\u00f6nisch W, Pl\u00f6tze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, AlAli HK, Niederwieser D (2015) Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV in newly diagnosed multiple myeloma. J Cancer Res Clin Oncol 141:2013\u20132022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl. 1","key":"2439_CR32","first-page":"263","volume":"4","author":"R Preiss","year":"2003","unstructured":"Preiss R, Teichert J, P\u00f6nisch W, Niederwieser D, Matthias M, Merkle KH (2003) Pharmacokinetics and toxicity profile of bendamustine in multiple myeloma patients with end-stage renal disease. Hematol J 4(Suppl. 1):263","journal-title":"Hematol J"},{"key":"2439_CR33","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.leukres.2010.04.024","volume":"34","author":"M Roussou","year":"2010","unstructured":"Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, Psimenou E, Gika D, Terpos E, Dimopoulos MA (2010) Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 34:1395\u20131397","journal-title":"Leuk Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2439-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T06:23:50Z","timestamp":1602138230000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2439-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["2439"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2439-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2017,5,22]]}}}